Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 112 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is L  [Clear All Filters]
2021
Zegarra-Ruiz DF, Kim DV, Norwood K, Kim M, Wu W-JH, Saldana-Morales FB, Hill AA, Majumdar S, Orozco S, Bell R et al..  2021.  Thymic development of gut-microbiota-specific T cells.. Nature. 594(7863):413-417.
Lima S, Gogokhia L, Viladomiu M, Chou L, Putzel G, Jin W, Pires S, Guo C-J, Gerardin Y, Crawford CV et al..  2021.  Transferable Immunoglobulin A-Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic Inflammation.. Gastroenterology.
Lima S, Gogokhia L, Viladomiu M, Chou L, Putzel G, Jin W, Pires S, Guo C-J, Gerardin Y, Crawford CV et al..  2021.  Transferable Immunoglobulin A-Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic Inflammation.. Gastroenterology.
Malik F, Scherl E, Weber U, Carrino JA, Epsten M, Wichuk S, Pedersen SJ, Paschke J, Schwartzman S, Kroeber G et al..  2021.  Utility of magnetic resonance imaging in Crohn's associated sacroiliitis: A cross-sectional study.. Int J Rheum Dis.
2020
Lukin DJ, Kumar A, Hajifathalian K, Sharaiha RZ, Scherl EJ, Longman RS.  2020.  Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.. Gastroenterology. 159(4):1541-1544.e2.
Lukin DJ, Kumar A, Hajifathalian K, Sharaiha RZ, Scherl EJ, Longman RS.  2020.  Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.. Gastroenterology. 159(4):1541-1544.e2.
Kumar A, Teslova T, Taub E, Miller JD, Lukin DJ.  2020.  Comorbid Diabetes in Inflammatory Bowel Disease Predicts Adverse Disease-Related Outcomes and Infectious Complications.. Dig Dis Sci.
Kumar A, Lukin D, Battat R, Schwartzman M, Mandl LA, Scherl E, Longman RS.  2020.  Defining the phenotype, pathogenesis and treatment of Crohn's disease associated spondyloarthritis.. J Gastroenterol. 55(7):667-678.
Kumar A, Lukin D, Battat R, Schwartzman M, Mandl LA, Scherl E, Longman RS.  2020.  Defining the phenotype, pathogenesis and treatment of Crohn's disease associated spondyloarthritis.. J Gastroenterol. 55(7):667-678.
Dulai PS, Singh S, Casteele NVande, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A et al..  2020.  Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.. Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Dulai PS, Singh S, Casteele NVande, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A et al..  2020.  Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.. Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Dulai PS, Singh S, Casteele NVande, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A et al..  2020.  Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.. Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel J-F, Lewis JD, Ghosh S et al..  2020.  Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.. Gastroenterology. 158(8):2123-2138.e8.
Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel J-F, Lewis JD, Ghosh S et al..  2020.  Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.. Gastroenterology. 158(8):2123-2138.e8.
Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel J-F, Lewis JD, Ghosh S et al..  2020.  Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.. Gastroenterology. 158(8):2123-2138.e8.
Ahmed W, Lukin DJ.  2020.  Finding a Needle in the Haystack? Defining the Role of Random Biopsies in IBD Dysplasia Surveillance. Inflamm Bowel Dis.
Kumar A, Lukin DJ.  2020.  Incident heart failure is a predictor of adverse outcomes in inflammatory bowel disease.. Eur J Gastroenterol Hepatol. 32(2):205-215.
Castellanos JG, Longman RS.  2020.  Innate lymphoid cells link gut microbes with mucosal T cell immunity.. Gut Microbes. 11(2):231-236.
Lukin DJ.  2020.  Predictors of Perianal Fistula Relapse in Crohn's Disease.. Inflamm Bowel Dis. 26(6):932-933.
Kumar A, Magro C, Lukin DJ.  2020.  Scattered Skin Eruptions in a Patient With Inflammatory Bowel Disease.. Gastroenterology.
Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT et al..  2020.  Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.. Aliment Pharmacol Ther. 52(11-12):1658-1675.
2019
Castellanos JG, Longman RS.  2019.  The balance of power: innate lymphoid cells in tissue inflammation and repair.. J Clin Invest. 129(7):2640-2650.
Agrawal M, Cohen-Mekelburg S, Kayal M, Axelrad J, Galati J, Tricomi B, Kamal K, Faye AS, Abrudescu P, Scherl E et al..  2019.  Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors.. Aliment Pharmacol Ther. 49(5):564-571.
Agrawal M, Cohen-Mekelburg S, Kayal M, Axelrad J, Galati J, Tricomi B, Kamal K, Faye AS, Abrudescu P, Scherl E et al..  2019.  Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors.. Aliment Pharmacol Ther. 49(5):564-571.
Lukin DJ, Lawlor G, Hudesman DP, Durbin L, Axelrad JE, Passi M, Cavaliere K, Coburn E, Loftus M, Jen H et al..  2019.  Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.. Inflamm Bowel Dis. 25(4):775-781.